The White House recently imposed sweeping new tariffs on a wide variety of imported goods.

The good news for patients is that pharmaceutical products are not subject to these so-called "reciprocal tariffs" -- for now. But that soon may change, as President Donald Trump has suggested that we'll still see pharma-specific tariffs "at some point."

Trump seems to expect this threat will force companies to move pharmaceutical manufacturing to the U.S. overnight. But in reality, upending longstanding global supply chains to shift manufacturing for even one product is a........

© International Business Times